论文部分内容阅读
现今以雌激素治疗绝经期症候群的2种给药方法,均不能令人满意。口服法不仅生物药效率高低不一,而且肠吸收后通过肝时,可刺激肝蛋白的合成及代谢,因此为确保疗效必需大剂量给药。经皮给药吸收率个体差异极大,且可发生局部皮肤反应。鉴于此,英国等欧洲6国联合研究组对鼻途径给雌激素的疗效和耐受性进行了大规模临床试验。 受试者为420例中、重度绝经期症候群患者年龄45～60岁,绝经时间6个月～5年。患者随机接受鼻
Both methods of administration of estrogen for the treatment of menopausal syndrome nowadays are unsatisfactory. Oral administration not only varies in bioavailability, but also can stimulate the synthesis and metabolism of hepatic protein when it is passed through the liver after intestinal absorption. Therefore, it is necessary to administer large doses to ensure efficacy. Transdermal drug absorption rates vary widely among individuals and may result in localized skin reactions. In view of this, the UK and other six European joint research team conducted a large-scale clinical trial on the efficacy and tolerability of nasal route to estrogen. Subjects were 420 patients with moderate and severe menopausal symptoms age 45 to 60 years, menopausal time of 6 months to 5 years. Patients randomized to the nose